BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw strong trading volume on Friday . 3,973,376 shares changed hands during mid-day trading, an increase of 160% from the previous session’s volume of 1,529,526 shares.The stock last traded at $5.00 and had previously closed at $4.85.

A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, August 18th. Royal Bank of Canada began coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $6.00 price target on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 5th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, November 8th. Finally, J P Morgan Chase & Co lifted their price objective on shares of BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a report on Wednesday, September 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $9.13.

The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). The firm had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $5.05 million. BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.16) earnings per share. research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.71 earnings per share for the current year.

In other BioCryst Pharmaceuticals news, Director Fred E. Cohen sold 54,250 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares in the company, valued at approximately $941,237.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO William P. Sheridan sold 64,310 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $4.72, for a total transaction of $303,543.20. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. grew its holdings in BioCryst Pharmaceuticals by 23.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 333,373 shares of the biotechnology company’s stock worth $2,801,000 after acquiring an additional 62,792 shares in the last quarter. Vanguard Group Inc. grew its holdings in BioCryst Pharmaceuticals by 19.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock worth $33,404,000 after acquiring an additional 996,052 shares in the last quarter. OxFORD Asset Management LLP acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $660,000. RA Capital Management LLC grew its holdings in BioCryst Pharmaceuticals by 47.9% during the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock worth $28,702,000 after acquiring an additional 1,672,447 shares in the last quarter. Finally, Swiss National Bank grew its holdings in BioCryst Pharmaceuticals by 49.9% during the 3rd quarter. Swiss National Bank now owns 171,300 shares of the biotechnology company’s stock worth $898,000 after acquiring an additional 57,000 shares in the last quarter. Institutional investors own 84.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BioCryst Pharmaceuticals (BCRX) Sees Unusually-High Trading Volume” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/biocryst-pharmaceuticals-bcrx-sees-unusually-high-trading-volume/1766673.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.